PL363362A1 - Leczenie guzów opornych z zastosowaniem pochodnych epotilonu - Google Patents

Leczenie guzów opornych z zastosowaniem pochodnych epotilonu

Info

Publication number
PL363362A1
PL363362A1 PL02363362A PL36336202A PL363362A1 PL 363362 A1 PL363362 A1 PL 363362A1 PL 02363362 A PL02363362 A PL 02363362A PL 36336202 A PL36336202 A PL 36336202A PL 363362 A1 PL363362 A1 PL 363362A1
Authority
PL
Poland
Prior art keywords
treatment
epothilone derivatives
refractory tumors
tumors
refractory
Prior art date
Application number
PL02363362A
Other languages
English (en)
Inventor
Francis Y.F. Lee
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23028846&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL363362(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL363362A1 publication Critical patent/PL363362A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL02363362A 2001-02-20 2002-02-06 Leczenie guzów opornych z zastosowaniem pochodnych epotilonu PL363362A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26983601P 2001-02-20 2001-02-20
PCT/US2002/004255 WO2002066038A1 (en) 2001-02-20 2002-02-06 Treatment of refractory tumors using epothilone derivatives

Publications (1)

Publication Number Publication Date
PL363362A1 true PL363362A1 (pl) 2004-11-15

Family

ID=23028846

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02363362A PL363362A1 (pl) 2001-02-20 2002-02-06 Leczenie guzów opornych z zastosowaniem pochodnych epotilonu

Country Status (18)

Country Link
US (2) US6686380B2 (pl)
EP (1) EP1385529A4 (pl)
JP (1) JP2004522774A (pl)
KR (1) KR20040025895A (pl)
CN (1) CN1774253A (pl)
BG (1) BG108075A (pl)
BR (1) BR0207487A (pl)
CA (1) CA2438610A1 (pl)
EE (1) EE200300396A (pl)
HU (1) HUP0303175A2 (pl)
IL (1) IL156988A0 (pl)
IS (1) IS6918A (pl)
MX (1) MXPA03007394A (pl)
NO (1) NO20033684L (pl)
PL (1) PL363362A1 (pl)
RU (1) RU2003128311A (pl)
WO (1) WO2002066038A1 (pl)
ZA (1) ZA200306173B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
SK8552003A3 (en) * 2001-01-25 2004-06-08 Bristol Myers Squibb Co Parenteral formulation containing epothilone analogs
ATE554756T1 (de) * 2001-03-14 2012-05-15 Bristol Myers Squibb Co Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP2006504743A (ja) 2002-10-09 2006-02-09 コーザン バイオサイエンシス インコーポレイテッド 治療製剤
TW200503738A (en) * 2003-07-16 2005-02-01 Tzu Chi Buddhist General Hospital Method for extracting antineoplastic components from bupleurum scorzonerifolium
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
WO2006017761A2 (en) * 2004-08-05 2006-02-16 Emory University Epothilone analogues as therapeutic agents
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
SI1817013T1 (sl) 2004-11-18 2008-12-31 Bristol Myers Squibb Co Peleta z gastrorezistentno oblogo, ki vsebuje iksabepilon
EP2634252B1 (en) 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
US8008256B2 (en) 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
US8463852B2 (en) * 2006-10-06 2013-06-11 Oracle International Corporation Groupware portlets for integrating a portal with groupware systems
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
CA2927832C (en) 2010-05-18 2021-03-23 Cerulean Pharma Inc. Cyclodextrin-containing polymer-therapeutic agent conjugates and their use
EP4087545A1 (en) 2020-01-10 2022-11-16 R-Pharm US Operating LLC Compositions of ixabepilone

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
EP0777472A2 (en) * 1994-08-31 1997-06-11 Eli Lilly And Company Methods for identifying and treating resistant tumors
DE59609305D1 (de) 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
US5969145A (en) 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
ATE267197T1 (de) 1996-11-18 2004-06-15 Biotechnolog Forschung Gmbh Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
EP0975638B1 (de) 1997-02-25 2002-08-07 Gesellschaft für biotechnologische Forschung mbH (GBF) Seitenkettenmodifizierte epothilone
HUP0003450A3 (en) 1997-03-06 2001-10-29 Harry Nijenhuis Man B V Terminal for transferring containers and a container car
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
JP4065573B2 (ja) 1997-04-18 2008-03-26 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
DK1001951T3 (da) 1997-07-16 2002-12-23 Schering Ag Thiazolderivater, fremgangsmåde til fremstilling deraf og anvendelse af disse
ES2290993T3 (es) 1997-08-09 2008-02-16 Bayer Schering Pharma Aktiengesellschaft Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
US6982142B2 (en) * 1997-12-01 2006-01-03 John Wayne Cancer Institute Methods for screening therapeutically effective agents
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
KR20080016756A (ko) 1998-02-05 2008-02-21 노파르티스 아게 유기화합물 함유 조성물
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
CA2322157C (en) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
AU5036999A (en) 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
CN100381566C (zh) 1998-11-20 2008-04-16 科森生物科学公司 产生环氧噻酮及其衍生物的重组方法和材料
BR9916833A (pt) 1998-12-22 2001-09-25 Novartis Ag Derivados de epotilona e seu uso como agentes antitumor
EE200100431A (et) 1999-02-18 2002-12-16 Schering Aktiengesellschaft 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
EE04852B1 (et) 1999-02-22 2007-06-15 Gesellschaft Fuer Biotechnologische Forschung Mbh C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
AR023792A1 (es) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
FR2793288B1 (fr) 1999-05-06 2001-07-20 Transrol Rotule permettant la transmission d'un couple
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
DE60225666T2 (de) 2001-01-25 2009-04-16 Bristol-Myers Squibb Co. Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
SK8552003A3 (en) 2001-01-25 2004-06-08 Bristol Myers Squibb Co Parenteral formulation containing epothilone analogs
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
ATE554756T1 (de) 2001-03-14 2012-05-15 Bristol Myers Squibb Co Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
WO2003105828A1 (en) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
HRP20050278A2 (en) 2002-09-23 2005-10-31 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
US7460891B2 (en) 2002-10-21 2008-12-02 Microsoft Corporation Method and system to shut down and control computer radios

Also Published As

Publication number Publication date
BG108075A (bg) 2005-04-30
WO2002066038A1 (en) 2002-08-29
RU2003128311A (ru) 2005-03-10
US20020165258A1 (en) 2002-11-07
MXPA03007394A (es) 2003-12-04
USRE41393E1 (en) 2010-06-22
NO20033684D0 (no) 2003-08-19
JP2004522774A (ja) 2004-07-29
HUP0303175A2 (hu) 2003-12-29
KR20040025895A (ko) 2004-03-26
BR0207487A (pt) 2004-08-10
ZA200306173B (en) 2004-11-23
US6686380B2 (en) 2004-02-03
IL156988A0 (en) 2004-02-08
IS6918A (is) 2003-08-18
NO20033684L (no) 2003-10-13
EE200300396A (et) 2003-12-15
CA2438610A1 (en) 2002-08-29
EP1385529A4 (en) 2007-05-09
EP1385529A1 (en) 2004-02-04
CN1774253A (zh) 2006-05-17

Similar Documents

Publication Publication Date Title
EP1385529A4 (en) TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES
PL363363A1 (pl) Pochodne epotilonu do leczenia opornych guzów
IL157425A0 (en) Treatment of solid tumours with paramycin derivatives
PT1438306E (pt) Derivados de uk-20
IL152754A0 (en) Quinazoline derivatives for the treatment of tumours
GB2393202B (en) Methods of well treatment
PL370029A1 (pl) Pochodne 2-amino-4-heteroaryloaminopirymidyny do stosowania w leczeniu raka
AU2002364300A8 (en) Polymer derivatives for the treatment of metals
AU2002328952A1 (en) Irinotecan for treatment of cancer
PL373912A1 (pl) Heterocykliczne pochodne do leczenia raka i innych chorób proliferacyjnych
PL369062A1 (pl) Pochodne arylo (lub heteroarylo) azolilokarbinolido leczenia nietrzymania moczu
HRP20030677A2 (en) Methods of administering epothilone analogs for the treatment of cancer
GB0124124D0 (en) Methods of treatment
HUP0402298A3 (en) Use of desoxypeganine for treating clinical depression
HK1060291A (en) Treatment of refractory tumors using epothilone derivatives
HK1057482A (en) Epothilone derivatives for the treatment of refractory tumors
PL352959A1 (en) Method of obtaining derivatives of taxane
GB0129451D0 (en) Treatment of cancer
GB0129388D0 (en) Use of compounds for treating cancer
GB0219811D0 (en) Treatment of excreta
SI1413305T1 (sl) Aril (ali heteroaril) azolikarbonil derivati za zdravljenje urinske inkontinence
GB0008161D0 (en) Treatment of cancer
SI1332137T1 (sl) Zdravljenje gastrointestinalnih stromalnih tumorjev
GB0109520D0 (en) Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as njk-inhibitors
AU2002254030A1 (en) Treatment of schizophrenia

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)